Last reviewed · How we verify
NCT06019312
L. Plantarum 299v and Gut Microbiome, Diarrhoea, and Clostridioides Difficile Infection in Colorectal Cancer Patients
NA trial testing Sanprobi IBS® in Colorectal Cancer in 60 participants. Status unknown.
30 May 2024
Quick facts
| Lead sponsor | Medical University of Gdansk |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 1 August 2023 |
| Primary completion | 30 May 2024 |
| Estimated completion | 1 June 2024 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Sanprobi IBS®
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Clostridioides Difficile Infection — all drugs for Clostridioides Difficile Infection →
- Diarrhea — all drugs for Diarrhea →
Sponsor
Medical University of Gdansk
Who can join
Adults 18 to 65, any sex, with Colorectal Cancer or Clostridioides Difficile Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Colorectal cancer in periooperative period patients (n=60) will be enrolled to this study. Participants will be divided into 4 groups as follows: * group 1 (n=15) will receive 2 capsules (per day) of L. plantarum 299v L. plantarum 299v (Sanprobi IBS®) for 4 weeks * group 2 (n=15) will receive L. plantarum 299v (2 capsules per day) and inulin (4 g) for 4 weeks * group 3 (n=15) will receive placebo (2 capsules per day) and inulin (4 g) for 4 weeks * group 4 (n=15) will receive placebo (2 capsules per day) for 4 weeks
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Role of the Microbiome in Cancer Therapies: Current Evidence and Future Directions.
Chalif J, Goldstein N, Mehra Y, Spakowicz D, et al · · 2025 · cited 5× · PMID 39856008 · DOI 10.1016/j.hoc.2024.12.005 -
Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets.
Wei W, Ren Y, Lan J, Yi J, et al · · 2026 · PMID 41507636 · DOI 10.1186/s43556-025-00358-4
Verify or expand the search:
- PubMed search for NCT06019312
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Medical University of Gdansk trials
Trials by the same sponsor.
- NCT07521280 — State-Based Rehabilitation for Youth Athletes With Osgood-Schlatter or Sever-Related Apophyseal Pain · NA · not yet recruiting
- NCT07446517 — Low-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth Athletes · NA · recruiting
- NCT07449585 — Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
- NCT07397208 — Assessment of the Repeatability of Sublingual Microcirculation Function Measurements in Healthy Volunteers and Criticall · not yet recruiting
- NCT07345403 — GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Ana · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06019312 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Gdansk
- Last refreshed: 31 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06019312.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing